SPRO
Spero Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 to Feb 6 ▼ 4 days of insider sells: $393.2K by 2 insiders, avg $2.29
- Mar 26 ▲ Spero Therapeutics reported a significant turnaround in financial pe…
- May 4 ▼ 1 insider sell $63.4K at $2.51
- Jun 17 ▲ Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipen…
- Jun 22 ▲ Spero Therapeutics and GSK announced FDA approval of Utebzi (tebipen…
- Jul 14 ▲ Spero Therapeutics in-licensed SP001 (IBI355), a Phase 2-ready anti-…
- Jul 14 FDA: Spero Therapeutics and Innovent Biologics Announce Exclusi…
- Aug 28 ▼ Spero Therapeutics entered into a new at-the-market (ATM) equity off…
- Aug 28 ▼ Spero Therapeutics filed a universal shelf registration statement (S…
- Sep 11 ▼ The SEC declared effective Spero Therapeutics' S-3 shelf registratio…
- Oct 28 Cantor Fitzgerald initiates
- Nov 9 ▼ 1 insider sell $42.5K at $1.04
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $499.1K.
- InstitutionsMIXED
Q3 2026: 7 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
7 of 9 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −6.4% to 787.0K shares. 2.2 days to cover, ≈1.4% of shares.
- TrendDOWNTREND
16% below its 50-day average. New closing low $0.9460 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.7M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $1.2M |
| RAYMOND JAMES FINANCIAL INC | ADD | $914.3K |
| MORGAN STANLEY | DOUBLED | $313.0K |
| Invesco Ltd. | DOUBLED | $200.3K |
| DIMENSIONAL FUND ADVISORS LP | TRIM | $110.4K |
| SIMPLEX TRADING, LLC | TRIM | $44.6K |
| JANE STREET GROUP, LLC | NEAR_EXIT | $24.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
9 analystsPrice is below the lowest target. Median implies +534%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 28, 2026 | Cantor Fitzgerald INITIATE | Overweight |
| Sep 14, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
HO WILLIAM Director Nov 10, 2026 | AWARD | 100,000 sh |
Rajavelu Esther See Remarks Nov 9, 2026 | SELL | $42.5K |
Zack Debra Chief Medical Officer Aug 3, 2026 | AWARD | 324,675 sh |
Zack Debra Chief Medical Officer Aug 3, 2026 | AWARD | 162,311 sh |
Pottage John C Jr Director Jun 23, 2026 | AWARD | 10,000 sh |
Jackson Scott Thomas Director Jun 23, 2026 | AWARD | 10,000 sh |
Pottage John C Jr Director Jun 23, 2026 | AWARD | 20,000 sh |
Jackson Scott Thomas Director Jun 23, 2026 | AWARD | 20,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.23 | -$0.23–-$0.23 | No data | $0.00 |
| Next Q | -$0.23 | -$0.23–-$0.23 | No data | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
13 filings · 4 press releases · 2 bullish · 3 bearish · 1 mixed · 7 neutral- NEUTRAL 8-KNov 12, 2026
Spero Therapeutics reported Q3 2026 results with no revenue and a net loss of $44.3 million ($0.76…
The company is now a pre-revenue clinical-stage biotech focused on SP001. Key catalysts are Phase 2 initiation in IgG4-RD (Q2 2027) and any future milestone payments from GSK on tebipenem HBr. Cash…
- NEUTRAL 3Nov 10, 2026
William Ho, M.D., Ph.D., filed a Form 3 initial statement of beneficial ownership with Spero…
Monitor future Form 4 filings for any insider transactions by William Ho, which could signal his view on the company's prospects. The appointment of a new director is routine and does not warrant…
- NEUTRAL 8-KNov 10, 2026
Spero Therapeutics disclosed the resignation of director Patrick Vink, M.D., effective November…
Monitor for any future board-level strategic shifts given the appointment of a director with clinical development and M&A experience, but no immediate catalyst from this routine governance change.
- NEUTRAL 8-KOct 27, 2026
Spero Therapeutics disclosed that COO Timothy Keutzer will retire effective December 31, 2026…
Monitor for announcement of a new COO or restructuring of executive responsibilities. The consulting period ends February 2027, so a permanent replacement may be named before or shortly after that…
All SPRO filing & press-release reports (17)
- 8-K reportNov 12, 2026
- 3 reportNov 10, 2026
- 8-K reportNov 10, 2026
- 8-K reportOct 27, 2026
- EFFECT reportSep 11, 2026
- 8-K reportAug 28, 2026
- S-3 reportAug 28, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportJul 14, 2026
- PRESS-RELEASE reportJul 14, 2026
- 8-K reportJun 25, 2026
- 8-K reportJun 22, 2026
- PRESS-RELEASE reportJun 17, 2026
- 8-K reportMay 13, 2026
- DEFA14A reportApr 27, 2026
- PRESS-RELEASE reportMar 26, 2026
- PRESS-RELEASE reportMar 18, 2026